


*Abstract*

5       The present invention is directed to carbocyclic hydrazino compounds that  
function as inhibitors of copper-containing amine oxidases commonly known as  
semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO  
known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have  
therapeutic utility as drugs to treat conditions and diseases including, but not  
10 limited to, a number of inflammatory conditions and diseases (in particular chronic  
inflammatory conditions such as chronic arthritis, inflammatory bowel diseases,  
and chronic skin dermatoses), diseases related to carbohydrate metabolism and to  
aberrations in adipocyte differentiation or function and smooth muscle cell  
function, and vascular diseases. The novel compounds have the general formula:

15



or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R<sup>1</sup> to  
R<sup>11</sup> are as defined herein.